Critical Care Medicine Department,
Clinical Center,
Critical Care Medicine Department, Clinical Center
Xizhong Cui has not added Biography.
If you are Xizhong Cui and would like to personalize this page please email our Author Liaison for assistance.
Inhaled nitric oxide: is systemic host defense at risk?
Critical care medicine Apr, 2002 | Pubmed ID: 11940783
Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis.
American journal of respiratory and critical care medicine Nov, 2002 | Pubmed ID: 12403688
Meta-analysis of acute lung injury and acute respiratory distress syndrome trials testing low tidal volumes.
American journal of respiratory and critical care medicine Dec, 2002 | Pubmed ID: 12406836
Protection with antibody to tumor necrosis factor differs with similarly lethal Escherichia coli versus Staphylococcus aureus pneumonia in rats.
Anesthesiology Jul, 2003 | Pubmed ID: 12826846
TGF-beta1 increases microbial clearance but worsens lung injury during Escherichia coli pneumonia in rats.
Cytokine Nov, 2003 | Pubmed ID: 14572790
Lethality during continuous anthrax lethal toxin infusion is associated with circulatory shock but not inflammatory cytokine or nitric oxide release in rats.
American journal of physiology. Regulatory, integrative and comparative physiology Apr, 2004 | Pubmed ID: 14715494
Activated protein C in sepsis: emerging insights regarding its mechanism of action and clinical effectiveness.
Current opinion in infectious diseases Jun, 2004 | Pubmed ID: 15166822
Severity of sepsis alters the effects of superoxide anion inhibition in a rat sepsis model.
Journal of applied physiology (Bethesda, Md. : 1985) Oct, 2004 | Pubmed ID: 15169752
Granulocyte colony-stimulating factor has differing effects comparing intravascular versus extravascular models of sepsis.
The Journal of trauma Sep, 2004 | Pubmed ID: 15454812
Recombinant human activated protein C in sepsis: assessing its clinical use.
The American journal of the medical sciences Oct, 2004 | Pubmed ID: 15486536
Late treatment with a protective antigen-directed monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsis.
The Journal of infectious diseases Feb, 2005 | Pubmed ID: 15633102
Neutrophil inhibition with L-selectin-directed MAb improves or worsens survival dependent on the route but not severity of infection in a rat sepsis model.
Journal of applied physiology (Bethesda, Md. : 1985) Jun, 2005 | Pubmed ID: 15677732
Mechanical ventilation in ARDS: One size does not fit all.
Critical care medicine May, 2005 | Pubmed ID: 15891350
Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial.
Critical care medicine Oct, 2005 | Pubmed ID: 16215410
Neutrophil stimulation with granulocyte colony-stimulating factor worsens ventilator-induced lung injury and mortality in rats.
Anesthesiology Nov, 2005 | Pubmed ID: 16249674
Antithrombotic therapies for sepsis: a need for more studies.
Critical care medicine Feb, 2006 | Pubmed ID: 16424739
Effective dosing of lipid A analogue E5564 in rats depends on the timing of treatment and the route of Escherichia coli infection.
The Journal of infectious diseases Mar, 2006 | Pubmed ID: 16453258
Sublethal doses of Bacillus anthracis lethal toxin inhibit inflammation with lipopolysaccharide and Escherichia coli challenge but have opposite effects on survival.
The Journal of infectious diseases Mar, 2006 | Pubmed ID: 16479518
Parthenolide has limited effects on nuclear factor-kappa beta increases and worsens survival in lipopolysaccharide-challenged C57BL/6J mice.
Cytokine Mar, 2006 | Pubmed ID: 16720096
DTPA Fe(III) decreases cytokines and hypotension but worsens survival with Escherichia coli sepsis in rats.
Intensive care medicine Aug, 2006 | Pubmed ID: 16775718
Lethal and edema toxins in the pathogenesis of Bacillus anthracis septic shock: implications for therapy.
American journal of respiratory and critical care medicine Feb, 2007 | Pubmed ID: 17095744
Bacillus anthracis edema and lethal toxin have different hemodynamic effects but function together to worsen shock and outcome in a rat model.
The Journal of infectious diseases Feb, 2007 | Pubmed ID: 17230417
Fluid support worsens outcome and negates the benefit of protective antigen-directed monoclonal antibody in a lethal toxin-infused rat Bacillus anthracis shock model.
Critical care medicine Jun, 2007 | Pubmed ID: 17452924
New insights into the pathogenesis and treatment of anthrax toxin-induced shock.
Expert opinion on biological therapy Jun, 2007 | Pubmed ID: 17555370
Neuronal nitric oxide synthase deficiency decreases survival in bacterial peritonitis and sepsis.
Intensive care medicine Nov, 2007 | Pubmed ID: 17684724
Risk of death does not alter the efficacy of hydrocortisone therapy in a mouse E. coli pneumonia model: risk and corticosteroids in sepsis.
Intensive care medicine Mar, 2008 | Pubmed ID: 17992512
Ethyl pyruvate decreased early nuclear factor-kappaB levels but worsened survival in lipopolysaccharide-challenged mice.
Critical care medicine Apr, 2008 | Pubmed ID: 18176313
Norepinephrine increases blood pressure but not survival with anthrax lethal toxin in rats.
Critical care medicine Apr, 2009 | Pubmed ID: 19242337
Antithrombosis Trials: Should we test therapeutic heparin adjusted based on activated partial thromboplastin time in septic shock?
Critical care medicine Apr, 2009 | Pubmed ID: 19318828
The heart is an early target of anthrax lethal toxin in mice: a protective role for neuronal nitric oxide synthase (nNOS).
PLoS pathogens May, 2009 | Pubmed ID: 19478875
Can we predict the effects of NF-kappaB inhibition in sepsis? Studies with parthenolide and ethyl pyruvate.
Expert opinion on investigational drugs Aug, 2009 | Pubmed ID: 19555300
Bacillus anthracis cell wall produces injurious inflammation but paradoxically decreases the lethality of anthrax lethal toxin in a rat model.
Intensive care medicine Jan, 2010 | Pubmed ID: 19756496
Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies.
Biologics : targets & therapy , 2009 | Pubmed ID: 19774207
Risk of death and the efficacy of eritoran tetrasodium (E5564): design considerations for clinical trials of anti-inflammatory agents in sepsis.
Critical care medicine Jan, 2010 | Pubmed ID: 20023474
Bundled care for septic shock: an analysis of clinical trials.
Critical care medicine Feb, 2010 | Pubmed ID: 20029343
SB203580, a p38 inhibitor, improved cardiac function but worsened lung injury and survival during Escherichia coli pneumonia in mice.
The Journal of trauma Jun, 2010 | Pubmed ID: 20068480
Anthrax lethal and edema toxins produce different patterns of cardiovascular and renal dysfunction and synergistically decrease survival in canines.
The Journal of infectious diseases Dec, 2010 | Pubmed ID: 21067373
Anthrax edema toxin has cAMP-mediated stimulatory effects and high-dose lethal toxin has depressant effects in an isolated perfused rat heart model.
American journal of physiology. Heart and circulatory physiology Mar, 2011 | Pubmed ID: 21217068
The effect of heparin administration in animal models of sepsis: a prospective study in Escherichia coli-challenged mice and a systematic review and metaregression analysis of published studies.
Critical care medicine May, 2011 | Pubmed ID: 21317646
Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies.
Expert opinion on drug metabolism & toxicology Apr, 2011 | Pubmed ID: 21323610
Delayed treatment with W1-mAb, a chimpanzee-derived monoclonal antibody against protective antigen, reduces mortality from challenges with anthrax edema or lethal toxin in rats and with anthrax spores in mice.
Critical care medicine Jun, 2011 | Pubmed ID: 21336113
Disruption of the transient receptor potential vanilloid 1 can affect survival, bacterial clearance, and cytokine gene expression during murine sepsis.
Anesthesiology May, 2011 | Pubmed ID: 21383614
Anthrax infection.
American journal of respiratory and critical care medicine Dec, 2011 | Pubmed ID: 21852539
The individual survival benefits of tumor necrosis factor soluble receptor and fluid administration are not additive in a rat sepsis model.
Intensive care medicine Oct, 2011 | Pubmed ID: 21922303
The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death.
Expert opinion on investigational drugs Nov, 2011 | Pubmed ID: 21961576
The potential contributions of lethal and edema toxins to the pathogenesis of anthrax associated shock.
Toxins Sep, 2011 | Pubmed ID: 22069762
Protective antigen antibody augments hemodynamic support in anthrax lethal toxin shock in canines.
The Journal of infectious diseases Mar, 2012 | Pubmed ID: 22223857
An overview of anthrax infection including the recently identified form of disease in injection drug users.
Intensive care medicine Jul, 2012 | Pubmed ID: 22527064
B. anthracis edema toxin increases cAMP levels and inhibits phenylephrine-stimulated contraction in a rat aortic ring model.
American journal of physiology. Heart and circulatory physiology Jul, 2013 | Pubmed ID: 23585140
Bacillus anthracis cell wall peptidoglycan but not lethal or edema toxins produces changes consistent with disseminated intravascular coagulation in a rat model.
The Journal of infectious diseases Sep, 2013 | Pubmed ID: 23737601
Antitumor necrosis factor therapy is associated with improved survival in clinical sepsis trials: a meta-analysis.
Critical care medicine Oct, 2013 | Pubmed ID: 23887234
The Surviving Sepsis Campaign's Revised Sepsis Bundles.
Current infectious disease reports Oct, 2013 | Pubmed ID: 23990342
B. anthracis associated cardiovascular dysfunction and shock: the potential contribution of both non-toxin and toxin components.
BMC medicine , 2013 | Pubmed ID: 24107194
Purified cell wall from the probiotic bacterium Lactobacillus gasseri activates systemic inflammation and, at higher doses, produces lethality in a rat model.
Critical care (London, England) , 2014 | Pubmed ID: 24989885
Tidal volume and plateau pressure use for acute lung injury from 2000 to present: a systematic literature review.
Critical care medicine Oct, 2014 | Pubmed ID: 25098333
Confirmed Bacillus anthracis infection among persons who inject drugs, Scotland, 2009-2010.
Emerging infectious diseases Sep, 2014 | Pubmed ID: 25148307
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved